Similar articles

Abstract: Objective: To study the therapeutic potential of Fas inhibition in different diseases, a Fas-targeting siRNA (small interfering)-expressing plasmid was constructed. Methods: The U6 promoter cassette and siFas (small interfering RNA that inhibit Fas expression) template sequence were obtained by PCR method. They were cloned into modified pcDNA3.1. The resultant plasmid pU6-siFas was transfected into P815 cells with lipofectin2000 and selected under G-418-containing culture medium. Fas inhibition in stably transfected cells was detected by immunocytochemistry. Results: The plasmid pU6-siFas efficiently reduced the expression of Fas and conferred G-418 resistance in P815 cells. Conclusion: The successful construction of the siRNA expressing plasmid will facilitate the application of RNA interference technique and lay the foundation for further study of Fas inhibition in the treatment of different diseases such as aplastic anemia and acute liver failure.

[1] Caplen, N.J., 2004. Gene therapy progress and prospects. Downregulating gene expression: The impact of RNA interference. Gene Therapy, 11:1241-1248.

[2] Emerman, M., Temin, H.M., 1984. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell, 39:449-467.

[3] Galle, P.R., Hofmann, W.J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P.H., Runkel, L., 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med., 182(5):1223-1230.

[4] Hirko, A., Tang, F., Hughes, J.A., 2003. Cationic lipid vectors for plasmid DNA delivery. Curr. Med. Chem., 10(14):1185-1193.

[5] Ismail, M., Gibson, F.M., Gordon-Smith, E.C., Rutherford, T.R., 2001. Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: Relationship with increased apoptosis and upregulation of Fas antigen. Br. J. Haematol., 113(3):706-712.

[6] Kaul, G., Amiji, M., 2004. Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles. J. Pharm. Sci., 94(1):184-198.

[7] Killick, S.B., Cox, C.V., Marsh, J.C., Gordon-Smith, E.C., Gibson, F.M., 2000. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: Examination of the role of the Fas-Fas-L interaction. Br. J. Haematol., 111(4):1164-1169.

[8] Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A., Herweijer, H., 2002. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nature Genetics, 32:107-108.

[9] Liu, S.H., Zhang, W.G., Cao, X.M., Yang, Y., Wang, Q.Y., Yang, G.X., 2003. Cloning and identification of U6+27 promoter cassettes. J Xi’an Jiaotong University (Medical Sciences), 24(suppl):54-55 (in Chinese).

[10] Maciejewski, J.P., Selleri, C., Sato, T., Anderson, S., Young, N.S., 1995. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br. J. Haematol., 91(1):245-252.

[11] McCaffrey, A.P., Meuse, L., Pham, T.T., Conklin, D.S., Hannon, G.J., Kay, M.A., 2002. RNA interference in adult mice. Nature, 418:38-39.

[12] Paul, C.P., Good, P.D., 2002. Effective expression of small interfering RNA in human cells. Nat. Biotech., 20:505-508.

[13] Song, E., Lee, S.K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., Lieberman, J., 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med., 9(3):347-351.

[14] Xia, H., Mao, Q., Paulson, H.L., 2002. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotech., 20:1006-1010.